$TNXP
Tonix Pharmaceuticals Holding Corp.

2015 Q2 Form 10-Q Financial Statement

#000114420415028828 Filed on May 08, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.910M $2.870M $1.620M
YoY Change 47.72% 77.16% 28.57%
% of Gross Profit
Research & Development $8.871M $6.829M $3.550M
YoY Change 117.69% 92.37% 379.08%
% of Gross Profit
Depreciation & Amortization $30.00K $22.00K $4.000K
YoY Change 200.0% 450.0% 0.0%
% of Gross Profit
Operating Expenses $11.78M $9.696M $5.169M
YoY Change 94.81% 87.58% 158.32%
Operating Profit -$11.78M -$9.696M -$5.169M
YoY Change 94.81% 87.58%
Interest Expense $20.00K $20.00K $10.00K
YoY Change 100.0% 100.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$11.76M -$9.680M -$5.160M
YoY Change 94.7% 87.6% 158.0%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.76M -$9.681M -$5.164M
YoY Change 94.62% 87.47% 158.07%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$588.0M -$968.0M -$516.0M
COMMON SHARES
Basic Shares Outstanding 16.14M shares 16.14M shares 9.899M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.70M $58.20M $49.50M
YoY Change 10.93% 17.58% 12275.0%
Cash & Equivalents $48.74M $58.18M $49.50M
Short-Term Investments
Other Short-Term Assets $1.600M $1.800M $600.0K
YoY Change 77.78% 200.0% 500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $50.31M $60.00M $50.10M
YoY Change 12.27% 19.76% 9920.0%
LONG-TERM ASSETS
Property, Plant & Equipment $316.0K $306.0K $0.00
YoY Change 345.07%
Goodwill
YoY Change
Intangibles $120.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $100.0K
YoY Change 0.0% 100.0% 0.0%
Total Long-Term Assets $614.0K $500.0K $100.0K
YoY Change 146.59% 400.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $50.31M $60.00M $50.10M
Total Long-Term Assets $614.0K $500.0K $100.0K
Total Assets $50.93M $60.50M $50.20M
YoY Change 13.01% 20.52% 8266.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.770M $2.000M $1.400M
YoY Change 82.48% 42.86% 55.56%
Accrued Expenses $1.849M $1.500M $600.0K
YoY Change 222.69% 150.0% 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $300.0K
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.619M $3.500M $2.300M
YoY Change 94.81% 52.17% 91.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $100.0K $0.00
YoY Change
Total Long-Term Liabilities $100.0K $100.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.619M $3.500M $2.300M
Total Long-Term Liabilities $100.0K $100.0K $0.00
Total Liabilities $4.684M $3.600M $2.300M
YoY Change 95.09% 56.52% 91.67%
SHAREHOLDERS EQUITY
Retained Earnings -$75.79M
YoY Change 99.78%
Common Stock $122.0M
YoY Change 51.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.24M $56.90M $47.92M
YoY Change
Total Liabilities & Shareholders Equity $50.93M $60.50M $50.20M
YoY Change 13.01% 20.51% 8267.33%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$11.76M -$9.681M -$5.164M
YoY Change 94.62% 87.47% 158.07%
Depreciation, Depletion And Amortization $30.00K $22.00K $4.000K
YoY Change 200.0% 450.0% 0.0%
Cash From Operating Activities -$9.240M -$9.050M -$4.060M
YoY Change 62.11% 122.91% 198.53%
INVESTING ACTIVITIES
Capital Expenditures -$150.0K $0.00 $2.000K
YoY Change 275.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$150.0K $0.00 $0.00
YoY Change 36.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $29.05M $40.65M
YoY Change -28.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -50.00K 29.05M 45.41M
YoY Change -138.46% -36.03%
NET CHANGE
Cash From Operating Activities -9.240M -9.050M -4.060M
Cash From Investing Activities -150.0K 0.000 0.000
Cash From Financing Activities -50.00K 29.05M 45.41M
Net Change In Cash -9.440M 20.00M 41.35M
YoY Change 66.2% -51.63% -3140.44%
FREE CASH FLOW
Cash From Operating Activities -$9.240M -$9.050M -$4.060M
Capital Expenditures -$150.0K $0.00 $2.000K
Free Cash Flow -$9.090M -$9.050M -$4.062M
YoY Change 60.6% 122.8% 198.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Cash
Cash
58181000 USD
CY2014Q4 us-gaap Cash
Cash
38184000 USD
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13696482 shares
CY2014Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6829000 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2867000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9696000 USD
CY2015Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
15000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9681000 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-3000 USD
CY2015Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3000 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9678000 USD
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 tnxp Issuance Of Common Stock To Intellectual Property
IssuanceOfCommonStockToIntellectualProperty
608000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
953000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
126000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
502000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
635000 USD
CY2015Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2014Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2015Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-289000 USD
CY2014Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-572000 USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40654000 USD
CY2015Q1 tnxp Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
29054000 USD
CY2015Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
70000 USD
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1348000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-5164000 USD
CY2015Q1 us-gaap Depreciation
Depreciation
22000 USD
CY2014Q1 us-gaap Depreciation
Depreciation
4000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1348000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
553000 USD
CY2015Q1 tnxp Issuance Of Common Stock To Intellectual Property
IssuanceOfCommonStockToIntellectualProperty
0 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-2000 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-2000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9053000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4064000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2000 USD
CY2015Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4758000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
29054000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
45412000 USD
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
-4000 USD
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
-1000 USD
CY2014Q1 us-gaap Cash
Cash
49547000 USD
CY2015Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
19997000 USD
CY2014Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
41345000 USD
CY2013Q4 us-gaap Cash
Cash
8202000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.0219 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0073 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0.0 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
313000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
446000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
459000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
442000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
99000 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
306000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
328000 USD
CY2015Q1 us-gaap Security Deposit
SecurityDeposit
45000 USD
CY2014Q4 us-gaap Security Deposit
SecurityDeposit
45000 USD
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16137898 shares
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1759000 USD
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16137898 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10805220 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10805220 shares
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
9696000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3550000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1619000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
5169000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5169000 USD
CY2014Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8718199 shares
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-2000 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2000 USD
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5162000 USD
CY2015Q1 us-gaap Other Commitment
OtherCommitment
26700000 USD
CY2015Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1 pure
CY2015Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.19 pure
CY2015Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
48107 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29054000 USD
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in accordance with&#160;accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of fixed assets, assumptions used in the fair value of stock-based compensation and other equity instruments, and the percent of completion of research and development contracts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1300000 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
600000 USD
CY2015Q1 tnxp Warrants Expired Number Of Warrants
WarrantsExpiredNumberOfWarrants
14538 shares
CY2015Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
70000 USD
CY2015Q1 tnxp Working Capital Amount
WorkingCapitalAmount
56500000 USD
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1731217 shares
CY2015Q1 tnxp Warrants Exercise Price
WarrantsExercisePrice
20.00
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Tonix Pharmaceuticals Holding Corp.
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001430306
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 dei Trading Symbol
TradingSymbol
TNXP
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16137898 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.24
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7143 shares
CY2015Q1 tnxp Common Stock Issued During Period Per Share Two
CommonStockIssuedDuringPeriodPerShareTwo
5.85
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2061 USD
CY2014Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
70000 USD
CY2015Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Risks and uncertainties</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company's primary efforts are devoted to conducting research and development for the treatment of disorders of the central nervous system. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated revenues and there is no assurance that if its products are approved for sale that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At March 31, 2015, the Company had working capital of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">56.5</font> million, after raising approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">29.1</font> million through the sale of common stock in an underwritten public&#160;offering in February 2015.&#160; Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 12 months. The Company expects that cash used in operations for research and development will increase significantly over the next several years.&#160;In the event the funding obtained is not sufficient to complete the development and commercialization of its current product candidates, the Company intends to raise additional funds through equity or debt financing. If the Company is unsuccessful in raising additional financing, it will need to reduce costs and operations in the future.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001144204-15-028828-index-headers.html Edgar Link pending
0001144204-15-028828-index.html Edgar Link pending
0001144204-15-028828.txt Edgar Link pending
0001144204-15-028828-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tnxp-20150331.xml Edgar Link completed
tnxp-20150331.xsd Edgar Link pending
tnxp-20150331_cal.xml Edgar Link unprocessable
tnxp-20150331_def.xml Edgar Link unprocessable
tnxp-20150331_lab.xml Edgar Link unprocessable
tnxp-20150331_pre.xml Edgar Link unprocessable
v409470_10q.htm Edgar Link pending
v409470_ex31-01.htm Edgar Link pending
v409470_ex31-02.htm Edgar Link pending
v409470_ex32-01.htm Edgar Link pending